TFF PHARMACEUTICALS INC (TFFP)

Company Profile

TFF Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2019-10-25. TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF), technology platform. The TFF platform is designed to improve the solubility of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The firm has two product candidates in clinical trials, which include TFF Voriconazole Inhalation Powder (TFF VORI) and TFF Tacrolimus Inhalation Powder (TFF TAC). TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment and prevention of invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF TAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine.

Company Info

TFF PHARMACEUTICALS INC

2600 Via Fortuna Ste 360

Austin TEXAS 78746

P: 17378021973

CEO: Glenn Mattes

Employees: 15

Website: https://tffpharma.com/